Advances in the targeted treatment of colorectal cancer underscore the central role of DNA mismatch repair and microsatellite instability (MMR/MSI) testing, which provide clinically actionable information for prognosis and treatment related decisions. However, different testing modalities, discordant and equivocal results and pitfalls in interpretation can complicate their use. In this activity, Drs. Tanios Bekaii-Saab and Rondell Graham will address these common concerns through case illustrations and data presentation. Lastly, a patient will detail his own personal journey with colon cancer.
Upon completion of this activity, participants should be better able to:
David F. and Margaret T. Grohne Professor
Novel Therapeutics for Cancer Research
Mayo Clinic College of Medicine and Science
Chairman, Division of Hematology/Medical Oncology
Mayo Clinic
Phoenix, AZ
Professor, Laboratory Medicine and Pathology
Mayo Clinic
Rochester, MN
Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.
Tanios S. Bekaii Saab, MD, has relevant financial relationship(s) with AbbVie, Aptitude Health, Arcus, Arsenal Bio, AstraZeneca, Bayer, Beigene, Blueprint Medicines, Boehringer Ingelheim, Caladrius Biosciences, Celularity, Daiichi Sankyo, Deciphera, Eisai, Exact Science, Exelixis, Foundation Medicine and Sanofi, Genentech, Glaxo SmithKline, Illumina, Incyte, Ipsen, Janssen, Kanaph, Merck KGaA, Merus, MJH Life Sciences, Natera, Pfizer, Revolution Medicines and Merck, Ryght AI, Seattle Genetics, Servier, Sobi, Stemline, Takeda, TreosBio, Xilio, Zai Labs (Consultant); Artiva, Immuneering, Imugene, Replimune, Xilis (Advisory Board); Abgenomics, Agios, Arcus, Arys, Atreca, Bayer, BMS, Boston Biomedical, Celgene, Clovis, Eisai, Genentech, Incyte, Ipsen, Lilly, Merus, Mirati, Novartis, Pfizer, Revolution Medicine, Seattle Genetics (Grant/Research Support).
Rondell P. Graham, MBBS, has relevant financial relationship(s) with AstraZeneca, Daiichi Sankyo (Advisor).
Patient participant in this activity has no relevant financial relationship(s) with ineligible companies to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated according to PACE policies.
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and RMEI Medical Education, LLC. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Partners for Advancing Clinical Education (Partners) designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
To receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity.
Users must:
There is no fee to participate.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Featured RMEI CE Activities
Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources
